newsfilter
← Latest News
GlobeNewswire·

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

  • IMUNON, Inc. will host its R&D Day on Wednesday, September 23, 2026, at 10:00 a.m. ET at the Sofitel New York or via live webcast.
  • The event will highlight IMNN-001, an investigational IL-12 immunotherapy, with a focus on the advancing Phase 3 OVATION 3 trial & Phase 2 MRD study.
  • Stacy Lindborg, Ph.D., President & CEO, will lead presentations on redefining frontline care & strategic milestones for the company.
  • Douglas V. Faller, M.D., Ph.D., Chief Medical Officer, will discuss overcoming historical barriers using the proprietary TheraPlas™ delivery system.
  • Experts including Amir Jazaeri, M.D., Premal H. Thaker, M.D., & William Bradley, M.D., will present translational insights & efficacy data from OVATION 2.
  • A unique segment will feature a conversation with an OVATION 1 clinical trial participant regarding her experience & long-term outcomes.
  • IMNN-001 utilizes a DNA plasmid nanoparticle system to enable persistent, local production of IL-12 protein for treating advanced ovarian cancer.
  • Previous trials showed positive safety & encouraging results for IMNN-001 as monotherapy & in combination with carboplatin & paclitaxel.
  • The Phase 2 OVATION 2 study assessed IMNN-001 plus neoadjuvant & adjuvant chemotherapy in 112 patients with newly diagnosed advanced ovarian cancer.
  • The company has completed dosing in a first-in-human study for its COVID-19 booster vaccine candidate, IMNN-101.
  • Registration is available in person or virtually by RSVPing through the provided link before the event date.
  • The event will conclude with a live Q&A session & networking opportunities for investors, media, & stakeholders.